Cancer Immunotherapy Clinical Trials In Singapore
Clinical trials play a pivotal role in evidence-based medicine. We believe that today’s research leads to tomorrow’s cure and our doctors are actively involved in clinical research and trials to bring new treatments and hope to our cancer patients. Clinical trials are a process that is internationally accepted to bring cancer immunotherapy medications to patients. The process is orderly and the findings about what the cancer drugs can or cannot do will benefit future patients. Side effects of these medications are recorded systematically as a basis to better inform doctors and patients.
At the same time, clinical trials for oncology drugs provide hope for patients and access to medications that might take some time to be developed. Some patients may feel like drugs are being “tested” on them. However, patients need to also understand that much of what we have learned about cancer medications has been from prior clinical trials. In addition, clinical trials are conducted in a way that aims to be fair to patients and investigators.
This systematic approach to clinical trials, prevalent in Singapore, ultimately enhances the quality of cancer care and paves the way for promising new treatments.
Contribution of Clinical Trials to Evidence-Based Medicine
Clinical trials form the cornerstone of evidence-based medicine, especially in cancer treatment. They offer a structured way to test new treatments or interventions, assess their effectiveness, and understand their side effects.
By ensuring that treatments provided to patients are safe and effective, clinical trials reduce the risk of harm and increase the probability of positive outcomes. They are central to the constant enhancement of Singapore’s healthcare sector, particularly oncology, by contributing to the development of new standards of care. Consequently, patients here can be assured they are receiving optimal care, informed by the latest and most rigorous scientific evidence. As a result, Singapore has become an emerging hub for advanced clinical trials, continuously contributing to the global understanding of cancer and its treatment.
Introduction to Phase 2 and Phase 3 Clinical Trials
Cancer treatment is established and developed through rigorous clinical research. At OncoCare Cancer Centre, we focus on Phase 2 and Phase 3 clinical trials for the benefit of patients. Phase 3 clinical trials are to compare if a new immunotherapy treatment is as good as or better than the current standard treatment for a particular cancer. The eligible patient will be assigned by computer to one of the study arms. Phase 2 clinical trials are to study if the new drug has specific therapeutic effects on certain cancers. The phase 2 drug has been investigated in prior settings to have a strong clinical rationale to work, especially as an alternative solution for patients in cases where commercially available treatment might have become less suitable or controlled the cancer’s progress. Through clinical trials, patients at OncoCare Cancer Centre can access commercially unavailable new and cutting-edge immunotherapy treatments with close monitoring.
Potential Benefits to Patients
Clinical trials for cancer immunotherapy hold the potential to revolutionise cancer treatment. By investigating novel ways to help the body’s immune system fight cancer, these trials can pave the way for new treatments that offer a better quality of life and improved survival rates. By participating, patients can gain access to new treatments before they are widely available and contribute to research that will benefit future generations.
Organisers of the Clinical Trials
Clinical trials are usually designed by medical expert working groups. It has to go through several rounds of approval by health authorities and ethics committees (EC)/ Institutional Review Board (IRB), with compliance to ICH guidelines (ICH stands for International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use), before any patients can be enrolled. The Institutional Review Board (IRB) or Ethics Committee (EC) is a committee made up of physicians, nurses, researchers, patients, and lawyers, to ensure that medical treatment and human research in such settings are carried out ethically by national and international law.
Clinical Trials Regulated in Singapore
The management and execution of clinical trials in Singapore are meticulously regulated under two key pieces of legislation – the Medicines Act from 1975 and the complementary Medicines (Clinical Trials) Regulations from 2000.
All patient-involved trials must receive approval from the Institutional Ethics Review Board, which ensures ethical conduct, and the Health Sciences Authority (HSA), ensuring safety regulations and robust methodologies are followed. These measures work in tandem to secure patient safety and rights during clinical trials.
The clinical trials framework aims to benefit current and future patients in the best way and to save as many lives as possible through methodical and systematic conduct of trials, information collection, and being mindful of patient safety.
Available Cancer Clinical Trials in Singapore
You are encouraged to look through our list of clinical trials in Singapore attached to find immunotherapy studies for which you may be eligible. Discuss with our doctors by booking an appointment at enquiries@oncocare.sg, or you could also reach us at clinicaltrials@oncocare.sg
Frequently Asked Questions about Clinical Trials in Singapore
Ethical considerations in conducting clinical trials for cancer treatments involve respect for patient autonomy, justice, beneficence, and non-maleficence. These principles are upheld through processes such as informed consent, ensuring participants fully understand the trial, its potential benefits, risks, and their right to withdraw at any time. Researchers also ensure that trials offer potential benefits to a diverse range of patients and that they minimise harm while maximising benefit.
Cancer immunotherapy clinical trials, like any treatment, can carry potential risks or side effects. These can range from minor symptoms like fatigue or nausea to more serious ones such as immune-related adverse events. The exact side effects will depend on the specific type of immunotherapy used, and these are explained in detail to participants before they consent to join the trial.
During clinical trials, side effects of cancer immunotherapy medications are meticulously recorded and monitored. Patients are regularly checked and asked about any symptoms they’re experiencing. Moreover, laboratory tests are often performed to detect any physical changes that could indicate side effects. This rigorous monitoring helps ensure patient safety and aids in understanding the treatment’s impact.
Once a patient completes a cancer immunotherapy clinical trial, there may be long-term effects or considerations to monitor, depending on the specific treatment tested. These could include ongoing monitoring for later effects of the treatment or assessing the long-term efficacy of the therapy. The research team will provide participants with detailed follow-up plans as needed.
Ensuring participant safety is paramount in clinical trials. Prior to the trial, the study protocol undergoes a thorough review by the Institutional Review Board (IRB). The IRB is composed of medical and non-medical members, tasked to ascertain that the trial does not present any unnecessary risks to the participants.
Participants are required to sign an “informed consent” form, which outlines the nature of the trial, potential risks, and the procedures involved. This document enables participants to understand fully what their participation entails. It is also important to note that this consent is given voluntarily, and participants are free to withdraw at any point during the trial without facing any penalty.
In line with stringent national and international standards, clinical trials ensure participants’ privacy and rights. Personal and medical information about participants is kept strictly confidential, and identifiable information is often replaced with codes in trial records to protect privacy.
Additionally, results from the trial are usually presented in a way that individual participants cannot be identified. This careful adherence to privacy protocols not only respects the participants’ rights but also promotes trust in the clinical trial process.
Active Clinical Trials - Recruiting Now
S/N | Indication | Study Title | Sponsor | Principal Investigator | Phase | Status | Study Drug | C3 | Colorectal Cancer | A Randomized Open-Label Phase 3 Study of XL092 +
Atezolizumab vs Regorafenib in Subjects with Metastatic
Colorectal Cancer (XL092-303) | Exelixis/ PRA | Dr Angela Pang | 3 | Recruiting | XL092 + Atezolizumab vs Regorafenib |
|---|---|---|---|---|---|---|---|
B10 | Breast cancer | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus In Patients With Estrogen Receptor-Positive, Her2-Negative, Locally Advanced Or Metastatic Breast Cancer (Ml43171) | GENENTEC/PPD | Dr Peter Ang | 3 | Recruiting | |
B9 | Breast cancer | A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
(VIKTORIA-1) | Celcuity, Inc. | Dr Wong Nan Soon | 3 | Recruiting | Gedatolisib+ Palbociclib+ Fulvestrant Vs Gedatolisib +Fulvestrant Vs Fulvestrant Vs Alpelisib +Fulvestrant |
LY2 | LYMPHOMA | “An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)” | Viracta Therapeutics, Inc./ Icon | Dr Kevin Tay Kuang Wei | 1/2 | Recruiting | Nanatinostat and Valganciclovir |
L12 | Non-Small-Cell Lung Cancer (NSCLC) | Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation( Mirati 12) | Mirati/ PRA | Dr Tan Chee Seng | 2 | Recruiting | MRTX849 Vs Docetaxel |
B9 | Breast Cancer | “A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) “ | Celcuity, Inc | Dr Wong Nan Soon | 3 | Recruiting | Gedatolisib+ Palbociclib+ Fulvestrant Vs Gedatolisib +Fulvestrant Vs Fulvestrant Vs Alpelisib +Fulvestrant |
C1 | Colorectal Cancer | Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy(Mirati 10) | Mirati/ PRA | Dr Thomas Soh I Peng | 3 | Recruiting | MRTX849 + Cetuximab Vs Chemotherapy |
L8 | Non-Small-Cell Lung Cancer (NSCLC) | Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Apollomics/ Medpace | Dr Leong Swan Swan | 2 | Recruiting | APL-101 |
Overall Study Status of All Clinical Trials at OncoCare
S/N | Indication | Study Title | Sponsor | Principal Investigator | Phase | Status | Study Drug | G5 | Gastric Cancer | A Randomized, Multicenter, Phase 3 Study of Zanidatamab in
Combination with Chemotherapy with or without Tislelizumab in
Subjects with HER2-positive Unresectable Locally Advanced or
Metastatic Gastroesophageal Adenocarcinoma (GEA) | BeiGene, Ltd. | Dr Thomas Soh I Peng | 3 | Recruitment closed | Trastuzumab + CAPOX or FP Vs Zanidatamab + CAPOX or FP Vs Zanidatamab + Tislelizumab + CAPOX or FP |
|---|---|---|---|---|---|---|---|---|
C1 | Colorectal Cancer | Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy(Mirati 10) | Mirati/ PRA | Dr Thomas Soh I Peng | 3 | Recruitment closed | MRTX849 + Cetuximab Vs Chemotherapy | |
C2 | Colorectal Cancer | A Randomized Open-Label Phase 3 Study of XL092 +
Atezolizumab vs Regorafenib in Subjects with Metastatic
Colorectal Cancer | Exelixis/ PRA | Dr Angela Pang | 3 | Recruitment closed | XL092 + Atezolizumab vs Regorafenib | |
E1 | Endometrial Cancer | “A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) “ | AstraZenaca/ Labcorp | Dr Lim Sheow Lei | 3 | Recruitment closed | Carboplatin + Paclitaxel + Durvalumab/ Placebo, followed by Durvalumab/ Placebo + Olaparib/ Placebo | |
B10 | Breast cancer | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171) | GENENTEC/PPD | Dr Peter Ang | 3 | Recruitment closed | GIREDESTRANT + EVEROLIMUS VS EXEMESTANE + EVEROLIMUS | |
L1 | Non-Small-Cell Lung Cancer (NSCLC) | A Randomized Phase 3 Study comparing First-Line Pemetrexed plus Cisplatin (followed by Gefitinib as maintenance) with Gefitinib monotherapy in East Asian (Never Smoker or Light Ex-Smoker) Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer | ELI LILY/ PAREXEL | Dr Leong Swan Swan | 3 | Recruitment closed | Alimta +cisplatin or Gefitinib alone | |
L2 | Lung Cancer | A Phase 3, Randomized, Open Label Study of The Efficacy and Safety of Crizotinib Versus Pemetrexed/ Cisplatin or Pemetrexed/ Carboplatin in Previously Untreated Patients With Non- Squamous Carcinoma of The Lung Harboring A Translocation or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus | PFIZER | Dr Leong Swan Swan | 3 | Recruitment closed | Crizotinib or Alimta+ carboplatin | |
L3 | Non-Small-Cell Lung Cancer (NSCLC) | A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI-906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | Astella Pharma/ PPD | Dr Leong Swan Swan | 2 | Recruitment closed | Tarceva + OSI-906/ Placebo | |
L4 | Non-Small-Cell Lung Cancer (NSCLC) | A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib | ARIAD/ PRA | Dr Leong Swan Swan | 2 | Recruitment closed | AP26113 | |
L5 | Non-Small-Cell Lung Cancer (NSCLC) | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | AZ | Dr Leong Swan Swan | 3 | Recruitment closed | MEDI4736 + Tremelimumab Vs Standard of Care Platinum-Based Chemotherapy | |
L6 | Non-Small-Cell Lung Cancer (NSCLC) | A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer | ARIAD/ PRA | Dr Leong Swan Swan | 3 | Recruitment closed | AP26113 (Brigitinib) Vs Crizotinib | |
L7 | Non-Small-Cell Lung Cancer (NSCLC)/Urothelial Carcinoma | A phase 1, open label, dose escalation and expansion study of PF-06801591 in patients with locally advanced or metastatic melanoma, squamous cell head and neck cancer, ovarian cancer, sarcoma, non-small cell lung cancer, urothelial carcinoma or other solid tumors. | Syneoshealth/ Pfizer | Dr Leong Swan Swan | 1 | Recruitment closed | PF-06801591 | |
L9 | Non-Small-Cell Lung Cancer (NSCLC) | A Phase 2 Study to Evaluate the safety and efficacy of AB122 Alone, AB154 in Combination with AB122 and AB928 in Front-Lin, Non-Small Cell Lung Cancer | Arcus Biosciences, Inc/ Novotech | Leong Swan Swan | 2 | Closed | AB122 Alone Vs AB154 + AB122 Vs AB154 + AB122 + AB928 | |
L13 | Non-Small-Cell Lung Cancer (NSCLC) | Randomized, Controlled, Open-label, Phase 3, Global Multi Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | Taiho/ PRA | Dr Leong Swan Swan | 3 | Recruiting | Zipalertinib + Chemotherapy Vs Chemotherapy | |
L14 | Non-Small-Cell Lung Cancer (NSCLC) | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. | Bayer | Dr Tan Chee Seng | 3 | To be activated soon | Bay2927088 Vs Chemotherapy | |
M1 | Multiple Myeloma | A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | Onyx/ Quintiles | Kevin Tay Kuang Wei | 3 | Closed | Carfilzomib+ Melphalan+ Prednisone Vs. Bortezomib+ Melphalan+ Prednisone | |
LY1 | LYMPHOMA | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND | MorphoSys AG./ Icon | Kevin Tay Kuang Wei | 2/3 | Recruitment closed | MOR00208 + Bendamustine Vs Rituximab +Bendamustine | |
L11 | Non-Small-Cell Lung Cancer (NSCLC) | Phase 3 Randomized Study of DS-1062a Versus Docetaxel In Previously Treated Advanced Or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung01) | Daiichi Sankyo/ SyneosHealth | Dr Tan Chee Seng | 3 | Recruitment closed | DS-1062a Vs Docetaxel | |
L10 | Non-Small-Cell Lung Cancer (NSCLC) | A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC) | Daiichi Sankyo/ SyneosHealth | Dr Leong Swan Swan | 2 | Recruitment closed | Patritumab Deruxtecan (U3-1402) | |
B8 | Breast Cancer | “A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting. (Destiny Breast 06) “ | AstraZenaca | Dr Peter Ang Cher Siang | 3 | Recruitment closed | Trastuzumab Deruxtecan (T-DXd) Vs Investigator’s Choice Chemotherapy | |
B7 | Breast Cancer | “A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290)” | AstraZenaca | Dr Tan Sing Huang | 3 | Closed | Capivasertib + Paclitaxel Vs Placebo + Paclitaxel | |
LY2 | LYMPHOMA | “An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)” | Viracta Therapeutics, Inc./ Icon | Dr Kevin Tay Kuang Wei | 1/2 | Recruiting | Nanatinostat and Valganciclovir | |
L12 | Non-Small-Cell Lung Cancer (NSCLC) | Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation( Mirati 12) | Mirati/ PRA | Dr Tan Chee Seng | 2 | Recruiting | MRTX849 Vs Docetaxel | |
B9 | Breast cancer | “A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) “ | Celcuity, Inc. | Dr Wong Nan Soon | 3 | Recruiting | Gedatolisib+ Palbociclib+ Fulvestrant Vs Gedatolisib +Fulvestrant Vs Fulvestrant Vs Alpelisib +Fulvestrant | |
C1 | Colorectal Cancer | Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy(Mirati 10) | Mirati/ PRA | Dr Thomas Soh I Peng | 3 | Recruiting | MRTX849 + Cetuximab Vs Chemotherapy | |
G5 | Gastric Cancer | “A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)” | BeiGene, Ltd. | Dr Thomas Soh I Peng | 3 | Recruiting | Trastuzumab + CAPOX or FP Vs Zanidatamab + CAPOX or FP Vs Zanidatamab + Tislelizumab + CAPOX or FP | |
P1 | Prostate Cancer | A Double Blind, Randomised, Multiple Dose, Phase III, Multicentre Study Of Alpharadin™ In The Treatment Of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases | ALGETA/ PHARMANET | Dr Tay Miah Hiang | 3 | Closed | ALPHARADIN | |
P2 | Prostate Cancer | A multicenter, randomized, double-blind study comparing the efficacy and safety of aflibercept versus placebo administered every 3 weeks in patients treated with docetaxel/prednisone for metastastic androgen-independent prostate cancer | SANOFI-AVENTIS | Dr Tay Miah Hiang | 3 | Closed | Aflibercept/placebo + taxotere | |
P3 | Prostate Cancer | A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK‑700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy‑Naïve Metastatic Castration-Resistant Prostate Cancer | Millenium/ PPD | Dr Tay Miah Hiang | 3 | Closed | TAK-700/ Placebo | |
P4 | Prostate Cancer | A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostrate Cancer That Has Progressed During or Following Docetaxel-based Therapy | Millenium/ PPD | Dr Tay Miah Hiang | 3 | Closed | TAK-700/ Placebo | |
P5 | Prostate Cancer | An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy | J&J | Dr Tay Miah Hiang | EAP | Closed | Abiraterone Acetate | |
P6 | Prostate Cancer | MULTICENTRE, SINGLE-ARM, OPEN LABEL CLINICAL TRIAL INTENDED TO PROVIDE EARLY ACCESS TO CABAZITAXEL IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER PREVIOUSLY TREATED WITH A DOCETAXEL-CONTAINING REGIMEN AND TO SAFETY OF CABAZITAXEL IN THESE PATIENTS | SANOFI-AVENTIS | Dr Tay Miah Hiang | EAP | Closed | CABAZITAXEL | |
P7 | Prostate Cancer | A Single-arm, international, prospective, interventional, open-label, multicenter study of Radium-223 dichloride in the treatment of patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastasis | BAYER | Dr Tay Miah Hiang | 3 | Closed | Radium-223 dichloride | |
P8 | Prostate Cancer | A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC) | BAYER/ Covance | Dr Tay Miah Hiang | 3 | Closed | Radium-223 dichloride / Abiraterone | |
P9 | Prostate Cancer | A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone | BI | Dr Tay Miah Hiang | 2 | Closed | BI 836845+ Enzalutamide Vs Enzalutamide | |
P10 | Prostate Cancer | A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis | Astella | Dr Tay Miah Hiang | 4 | Closed | NA | |
P11 | Prostate Cancer | A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX) | BMS/ Syneos Health | Dr Tay Miah Hiang | 3 | Closed | Nivolumab + Docetaxel Vs Placebo + Docetaxel | |
P12 | Prostate Cancer | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | Exelixis/ PRA | Dr Tay Miah Hiang | 3 | Closed | Cabozantinib (XL184) + Atezolizumab Vs Second Novel Hormonal Therapy (NHT) | |
R1 | Renal cell carcinoma (RCC) – Kidney cancer | A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney | NOVARTIS/ PAREXEL | Dr Tay Miah Hiang | 2 | Closed | Everolimus/ interferon +Bevacizumab | |
R2 | Renal cell carcinoma (RCC) – Kidney cancer | A Phase III, Open-label, Randomized Study of Atezolizumab (Anti PD- L1 Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma | ROCHE | Dr Tay Miah Hiang | 3 | Closed | Atezolizumab (Anti PD- L1 Antibody) + Bevacizumab vs Sunitinib | |
R3 | Renal cell carcinoma (RCC) – Kidney cancer | A Phase lll, Randomised, Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Ivestigator’s Choice of Sunitinib or Cabozantinib in Patients with previously Untreated Advanced Renal Cell Carcinoma | Nektar/ PPD | Dr Thomas Soh I Peng Dr Tay Miah Hiang | 3 | Closed | NKTR-214 + Nivolumab Vs Sunitinib or Cabozantinib | |
U1 | Urothelial Carcinoma | A Phase III, Multicenter, Randomized, Placebo-controlled Study of Atezolizumab (Anti-PD-L1 Antibody) As Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | ROCHE | Dr Tay Miah Hiang | 3 | Closed | NKTR-214 + Nivolumab Vs Sunitinib or Cabozantinib | |
H1 | Hepatocellular carcinoma (HCC) – Liver cancer | Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib | BAYER | Dr Tay Miah Hiang | 4 | Closed | Sorafenib | |
H2 | Hepatocellular carcinoma (HCC) – Liver cancer | A phase II trial of BAY 86-9766 plus sorafenib as a first line systemic treatment for hepatocellular carcinoma (HCC) | BAYER | Dr Tay Miah Hiang | 2 | Closed | Sorafenib + Bay 86-9766 | |
H3 | Hepatocellular carcinoma (HCC) – Liver cancer | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma | BMS/ Syneos Health | Dr Thomas Soh I Peng | 3 | Recruitment closed | Nivolumab + Ipilimumab Vs Sorafenib or Lenvatinib | |
H4 | Hepatocellular carcinoma (HCC) – Liver cancer | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2) | AstraZenaca | Dr Thomas Soh I Peng | 3 | Recruitment closed | Durvalumab Monotherapy or Durvalumab + Bevacizumab | |
G1 | Gastrointestinal Stromal Tumor (GIST) | Safety and Effectiveness of Regorafenib in Routine Clinical Practice | BAYER | Dr Tay Miah Hiang | 4 | Closed | Ragorefenib | |
G2 | Gastric Cancer | A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine | IMCLONE/ PAREXEL | Dr Peter Ang Cher Siang | 3 | Closed | Ramucirumab/ Placebo + Paclitaxel | |
G3 | Gastric Cancer | A Randomized, Phase II, Placebo Controlled Study of GDC-0068, An Inhibitor to AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adendocarcinoma | GENENTECH /PPD | Dr Wong Nan Soon | 2 | Closed | GDC_0068+ Fluoropyrimidine + Oxaliplatin | |
G4 | CA Gastric and Gastroesophageal Junction (GEJ) | A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585) | MSD | Dr Thomas Soh I Peng | 3 | Closed | Pembrolizumab (MK-3475) + XP/FP Vs Placebo + XP/FP | |
B1 | Breast cancer | A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy | BAYER | Dr Wong Nan Soon | 3 | Closed | Xofigo Vs placbo | |
B2 | Breast cancer | A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases | BAYER | Dr Wong Nan Soon | 3 | Closed | Xofigo/ Placebo + exemestane + everolimus | |
B3 | Breast cancer | A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer | CELLTRION/ PAREXEL | Dr Peter Ang Cher Siang | 3 | Closed | Herceptin/ CT-P6 + Paclitaxel | |
B4 | Breast cancer | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA) | PUMA/ NOVETECH | Dr Peter Ang Cher Siang | 3 | Closed | Neratinib + Capecitabine Vs Lapatinib + Capecitabine | |
B5 | Breast cancer | A randomized, phase II, multicenter, placebo-controlled study of Ipatasertib (GDC-0068), an inhibitor of AKT, in combination with Paclitaxel as front-line treatment for patients with metastatic triple-negative breast cancer | GENENTEC | Dr Peter Ang Cher Siang | 2 | Closed | GDC_0068+ Paclitaxel | |
B6 | Breast cancer | A Phase ll, Randimised Study of the Combination of Ribociclib plus Goserelin Acetate with Hormonal Therapy versus physician choice Chemotherapy in Premenopausal or Perimenopausal patients with hormone receptor – positive/HER2-negative inoperable locally advanced or metastatic breast cancer-Right Choice Study | Novartis | Dr Peter Ang Cher Siang | 2 | Closed | Ribociclib + Goserelin Acetate +Letrozole/Anastrzole Vs Doce+Cape or Pac+Gem or Cape+Vino |
